Lowering INR using four factor prothrombin complex concentrate for procedures in patients with ventricular assist devices: A case series
Journal Title: Journal of Hematology and Therapeutics - Year 2016, Vol 1, Issue 1
Abstract
This case series describes the use of four factor prothrombin complex concentrate (4FPCC) to reverse warfarin anticoagulation without the need for pre-procedure bridging with a parenteral agent or the use of FFP or vitamin K in patients with ventricular assist devices (VAD) who require invasive procedures. Patients were included if they had a history of recent warfarin use and documentation of temporary warfarin reversal for the procedure. Patients were excluded if their first dose of 4FPCC was for active bleeding. INR was assessed prior to 4FPCC administration, and trended for at least 90 h afterwards. Charts were reviewed for adverse events. In patients who received only 4FPCC for INR correction, the mean INR before 4FPCC was given was 2.7 (SD 0.64), which dropped an average of 35.4% after administration to a mean INR of 1.6 (SD 0.30). In the two patients who also received vitamin K, the average INR before reversal was 2.0 (SD 0.49), and was reduced by 35.9% to 1.3 (SD 0.21). The average number of days until patients re-established a therapeutic INR with 4FPCC alone was 3.2 days post procedure compared to 8.5 days for patients who received concomitant vitamin K. No bleeding or thrombotic events were observed. Using 4FPCC without vitamin K may provide VAD patients and clinicians with safe, effective, and rapid reversal of warfarin with faster recovery to the target INR following the procedure.
Authors and Affiliations
Nashett RM, Sylvester K, Connors JM
Keywords
Related Articles
- EP ID EP560049
- DOI 10.14312/2397-8694.2016-1
- Views 25
- Downloads 0
Lowering INR using four factor prothrombin complex concentrate for procedures in patients with ventricular assist devices: A case series
This case series describes the use of four factor prothrombin complex concentrate (4FPCC) to reverse warfarin anticoagulation without the need for pre-procedure bridging with a parenteral agent or the use of FFP or vitam...
In vitro chemosensitivity study of human leukemic cells in a three-dimensional bone marrow culture system
In the bone marrow, hematopoietic stem cell proliferation and differentiation are regulated by the hematopoietic microenvironment. This is reflected by the ability of the bone marrow microenvironment to alter the growth...
Unexpected insights in the aetiology and management of abdominal vein thrombosis
Myeloproliferative neoplasms (MPN) – polycythaemia vera (PV) and essential thrombocythaemia (ET) are common causes of abdominal vein thrombosis (portal and hepatic veins). The JAK2 mutation is found in 50% of ET and 95%...